$CME

DUFFY TERRENCE A sold $4.1M of CME

DUFFY TERRENCE A (Chairman and CEO) sold 15,000 shares of CME GROUP INC. (CME) at an average of $274.44 ($274.41–$275.03, $4.12M total) across 2 trades on 2026-09-10.

Original reporting
SEC EDGAR · DUFFY TERRENCE A
Published Sep 11, 2026, 9:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 11:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CME
Bearish
medium confidence
Mentioned
$CME
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CMEBearishLow
01

Why it matters

The CEO's sale reduces his ownership, which may be interpreted by the market as a lack of confidence.

02

Market read

Insider sales are closely watched; this filing provides fresh data for traders.

03

What to watch

Potential upcoming corporate actions or compensation plans not disclosed.

Relevance 6/10Novelty 7/10Timing: post‑market 2026‑09‑10

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$CMEBearishMedium confidence
Context

CEO Terrence Duffy sold 15,000 shares for $4.1M, reducing his stake to 40,630 shares.

Expected impact

Possible short‑term dip or increased volatility.

Evidence & confidence

Sale size is material for a large‑cap, but no other catalyst is present.

Market effects

Minimal impact on financial services sector; may prompt scrutiny of other insider activity.

Negligible effect on broader U.S. market.

Limited to investors tracking CME Group.

Counterpoint

The sale could be routine portfolio rebalancing, not a bearish signal.

Key entities

  • CME Group Inc.

    Operator of global derivatives exchanges.

  • Terrence Duffy

    Chairman and CEO of CME Group.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CMEMed

FanDuel Gets FCM License, Raising Questions Over CME Role in Predicts

FanDuel has received a futures commission merchant (FCM) license from the National Futures Association, allowing it more control over its U.S. prediction market business. The approval raises questions about its partnership with CME Group, which holds a 51% stake in FanDuel Predicts. CME's CEO previously stated that such a license could conflict with their agreement. FanDuel's new license does not permit it to operate its own exchange, but it may seek further approvals in the future.

$CMEMed

Baseball may get its first stats-based trading contracts Oct. 12, pending regulatory review.

CME Group plans to launch baseball futures on October 12, 2026, pending regulatory approval. The contracts will track CME FutureSports Performance Indexes, based on official league data of 30 professional baseball teams. Standard contracts will be valued at 10x the indexes, while micro contracts will be 1/10 their value. Trading will begin with the 2026 Postseason and the four clubs in the League Championship Series.

$FLUTHigh

FanDuel Lands FCM License, But CME Isn’t Involved

FanDuel, owned by Flutter Entertainment (FLUT), secured a futures commission merchant (FCM) license from the National Futures Association. This approval may alter FanDuel's relationship with CME Group (CME), the majority owner of FanDuel Predicts. FanDuel has been expanding its prediction market operations, including a partnership with Crypto.com. CME has expressed concerns about FanDuel's potential competitive threat.